Cargando…

Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma

BACKGROUND: The pathological and clinical features of invasive lobular carcinoma (ILC) differ from those of invasive ductal carcinoma (IDC). Several studies have indicated that patients with ILC have a better prognosis than those with ductal carcinoma. However, no previous study has considered the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Yayoi, Ishiguro, Junko, Kotani, Haruru, Hisada, Tomoka, Ichikawa, Mari, Gondo, Naomi, Yoshimura, Akiyo, Kondo, Naoto, Hattori, Masaya, Sawaki, Masataka, Fujita, Takashi, Kikumori, Toyone, Yatabe, Yasushi, Kodera, Yasuhiro, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807554/
https://www.ncbi.nlm.nih.gov/pubmed/27015895
http://dx.doi.org/10.1186/s12885-016-2275-4
_version_ 1782423395159244800
author Adachi, Yayoi
Ishiguro, Junko
Kotani, Haruru
Hisada, Tomoka
Ichikawa, Mari
Gondo, Naomi
Yoshimura, Akiyo
Kondo, Naoto
Hattori, Masaya
Sawaki, Masataka
Fujita, Takashi
Kikumori, Toyone
Yatabe, Yasushi
Kodera, Yasuhiro
Iwata, Hiroji
author_facet Adachi, Yayoi
Ishiguro, Junko
Kotani, Haruru
Hisada, Tomoka
Ichikawa, Mari
Gondo, Naomi
Yoshimura, Akiyo
Kondo, Naoto
Hattori, Masaya
Sawaki, Masataka
Fujita, Takashi
Kikumori, Toyone
Yatabe, Yasushi
Kodera, Yasuhiro
Iwata, Hiroji
author_sort Adachi, Yayoi
collection PubMed
description BACKGROUND: The pathological and clinical features of invasive lobular carcinoma (ILC) differ from those of invasive ductal carcinoma (IDC). Several studies have indicated that patients with ILC have a better prognosis than those with ductal carcinoma. However, no previous study has considered the molecular subtypes and histological subtypes of ILC. We compared prognosis between IDC and classical, luminal type ILC and developed prognostic factors for early breast cancer patients with classical luminal ILC. METHODS: Four thousand one hundred ten breast cancer patients were treated at the Aichi Cancer Center Hospital from 2003 to 2012. We identified 1,661 cases with luminal IDC and 105 cases with luminal classical ILC. We examined baseline characteristics, clinical outcomes, and prognostic factors of luminal ILC. RESULTS: The prognosis of luminal ILC was significantly worse than that of luminal IDC. The rates of 5-year disease free survival (DFS) were 91.9 % and 88.4 % for patients with luminal IDC and luminal ILC, respectively (P = 0.008). The rates of 5-year overall survival (OS) were 97.6 % and 93.1 % for patients with luminal IDC and luminal ILC respectively (P = 0.030). Although we analyzed prognosis according to stratification by tumor size, luminal ILC tended to have worse DFS than luminal IDC in the large tumor group. In addition, although our analysis was performed according to matching lymph node status, luminal ILC had a significantly worse DFS and OS than luminal IDC in node-positive patients. Survival curves showed that the prognosis for ILC became worse than IDC over time. Multivariate analysis showed that ILC was an important factor related to higher risk of recurrence of luminal type breast cancer, even when tumor size, lymph node status and histological grade were considered. CONCLUSIONS: Luminal ILC had worse outcomes than luminal IDC. Consequently, different treatment approaches should be used for luminal ILC than for luminal IDC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2275-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4807554
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48075542016-03-25 Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma Adachi, Yayoi Ishiguro, Junko Kotani, Haruru Hisada, Tomoka Ichikawa, Mari Gondo, Naomi Yoshimura, Akiyo Kondo, Naoto Hattori, Masaya Sawaki, Masataka Fujita, Takashi Kikumori, Toyone Yatabe, Yasushi Kodera, Yasuhiro Iwata, Hiroji BMC Cancer Research Article BACKGROUND: The pathological and clinical features of invasive lobular carcinoma (ILC) differ from those of invasive ductal carcinoma (IDC). Several studies have indicated that patients with ILC have a better prognosis than those with ductal carcinoma. However, no previous study has considered the molecular subtypes and histological subtypes of ILC. We compared prognosis between IDC and classical, luminal type ILC and developed prognostic factors for early breast cancer patients with classical luminal ILC. METHODS: Four thousand one hundred ten breast cancer patients were treated at the Aichi Cancer Center Hospital from 2003 to 2012. We identified 1,661 cases with luminal IDC and 105 cases with luminal classical ILC. We examined baseline characteristics, clinical outcomes, and prognostic factors of luminal ILC. RESULTS: The prognosis of luminal ILC was significantly worse than that of luminal IDC. The rates of 5-year disease free survival (DFS) were 91.9 % and 88.4 % for patients with luminal IDC and luminal ILC, respectively (P = 0.008). The rates of 5-year overall survival (OS) were 97.6 % and 93.1 % for patients with luminal IDC and luminal ILC respectively (P = 0.030). Although we analyzed prognosis according to stratification by tumor size, luminal ILC tended to have worse DFS than luminal IDC in the large tumor group. In addition, although our analysis was performed according to matching lymph node status, luminal ILC had a significantly worse DFS and OS than luminal IDC in node-positive patients. Survival curves showed that the prognosis for ILC became worse than IDC over time. Multivariate analysis showed that ILC was an important factor related to higher risk of recurrence of luminal type breast cancer, even when tumor size, lymph node status and histological grade were considered. CONCLUSIONS: Luminal ILC had worse outcomes than luminal IDC. Consequently, different treatment approaches should be used for luminal ILC than for luminal IDC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2275-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-25 /pmc/articles/PMC4807554/ /pubmed/27015895 http://dx.doi.org/10.1186/s12885-016-2275-4 Text en © Adachi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Adachi, Yayoi
Ishiguro, Junko
Kotani, Haruru
Hisada, Tomoka
Ichikawa, Mari
Gondo, Naomi
Yoshimura, Akiyo
Kondo, Naoto
Hattori, Masaya
Sawaki, Masataka
Fujita, Takashi
Kikumori, Toyone
Yatabe, Yasushi
Kodera, Yasuhiro
Iwata, Hiroji
Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
title Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
title_full Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
title_fullStr Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
title_full_unstemmed Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
title_short Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
title_sort comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807554/
https://www.ncbi.nlm.nih.gov/pubmed/27015895
http://dx.doi.org/10.1186/s12885-016-2275-4
work_keys_str_mv AT adachiyayoi comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT ishigurojunko comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT kotaniharuru comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT hisadatomoka comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT ichikawamari comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT gondonaomi comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT yoshimuraakiyo comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT kondonaoto comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT hattorimasaya comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT sawakimasataka comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT fujitatakashi comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT kikumoritoyone comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT yatabeyasushi comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT koderayasuhiro comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma
AT iwatahiroji comparisonofclinicaloutcomesbetweenluminalinvasiveductalcarcinomaandluminalinvasivelobularcarcinoma